News
AVTX
--
0.00%
--
RBC Capital Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $6
RBC Capital analyst Gregory Renza initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $6.
Benzinga · 1d ago
--RBC Initiates Avalo Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $6
MT Newswires · 1d ago
BRIEF-Point72 Asset Management Reports 5.4% Passive Stake In Avalo Therapeutics As Of Sept. 17
reuters.com · 4d ago
Point72 Asset Management Reports In 13G Filing A 5.4% Stake In Avalo Therapeutics
-SEC Filing
SEC Filing · 4d ago
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 5d ago
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant ...
GlobeNewswire · 5d ago
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for...
GlobeNewswire · 09/17 13:11
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Benzinga · 09/15 16:01
Melco Resorts & Entertainment, Hut 8 Mining, Theravance Biopharma among premarket losers' pack
Nuwellis (NASDAQ:NUWE) -28% after proposes stock offering Theravance Biopharma (NASDAQ:TBPH) -20% after ampreloxetine misses primary endpoint in late-stage orthostatic; on headcount cut to focus on respiratory disease portfolio hypotension study DAVIDsTEA ...
Seekingalpha · 09/15 12:26
Avalo Therapeutics Priced 12.5M Share Public Offering of Common Stock @$2.20/Share
Avalo Therapeutics, Inc.
Benzinga · 09/15 09:25
Avalo Therapeutics Prices Offering at $2.20/Share, Expects $27.5 Million Gross Proceeds
MT Newswires · 09/15 03:27
BRIEF-Avalo Therapeutics Inc Announces Pricing Of $27.5 Million Public Offering Of Common Stock
reuters.com · 09/15 02:24
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for...
GlobeNewswire · 09/15 02:23
BRIEF-Avalo Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
reuters.com · 09/14 20:03
Avalo Therapeutics' (NASDAQ:AVTX) investors will be pleased with their favorable 35% return over the last year
It's always best to build a diverse portfolio of shares, since any stock business could lag the broader market. But if...
Simply Wall St. · 09/06 10:43
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases Robust pipeline of six product candidates advancing in
Benzinga · 08/26 11:35
Cerecor Changes Name to Avalo Therapeutics
MT Newswires · 08/26 09:48
Insider Trends: 90-Day Buying Trend Prolonged with Insider Purchase of Cerecor Stock
MT Newswires · 08/18 18:01
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Nuwellis (NASDAQ:NUWE) shares increased by 5.63% to $4.5 during Friday's after-market session. The market value of their outstanding shares is at $29.3 million.
Benzinga · 08/06 20:31
Insider Trends: Insider Buying Continued with Purchase of Cerecor Stock
MT Newswires · 08/06 15:33
Webull provides a variety of real-time AVTX stock news. You can receive the latest news about Avalo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AVTX
Avalo Therapeutics, Inc., formerly Cerecor, Inc., is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes targeted therapeutics for patients with clinical need in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates include AVTX-002, AVTX-007, AVTX-006 and AVTX 800 programs. Its AVTX-002 is an Anti-LIGHT mAb targeting immune-inflammatory diseases including acute respiratory distress syndrome (ARDS) and moderate-to-severe inflammatory bowel disease. Its AVTX-007 is an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases including multiple myeloma and Still’s disease. Its AVTX-006 is a dual mTORc1/c2 inhibitor targeting lymphatic malformations. Its AVTX 800 programs include AVTX-801, AVTX-802 and AVTX-803. Its AVTX 800 programs is a therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).